Oxaliplatin-related neurotoxicity: how and why?
- PMID: 16806962
- DOI: 10.1016/j.critrevonc.2006.01.001
Oxaliplatin-related neurotoxicity: how and why?
Abstract
In early clinical trials, oxaliplatin has demonstrated significant activity against colorectal cancer in combination with 5-fluorouracil (5-FU) and folinic acid (FA), both in metastatic as in radically resected disease. The drug differs from the other two most important platinum compounds (cisplatin and carboplatin) for the absence of nephrotoxicity or for the reduced drug-induced ototoxicity. During its administration, two different types of neurological symptoms can be experienced: the first one occurs during or immediately after the end of the infusion and it appears as a transient peripheral sensory neuropathy manifesting as paresthesias and dysesthesia in the extremities sometimes accompanied by muscular contractions of the extremities or the jaw (triggered or enhanced by exposure to cold). The second one occurs after long-term administration of oxaliplatin presenting with deep sensory loss, sensory ataxia and functional impairment (similar to those observed with cisplatin). This type of neurotoxicity is usually late-onset and correlated with the cumulative-dose of oxaliplatin. The aim of this review is to analyse the mechanism underlying induction of neurotoxicity and the possible treatments to prevent and to treat it.
Similar articles
-
Pharmacokinetics and safety profile of oxaliplatin.Semin Oncol. 1998 Apr;25(2 Suppl 5):13-22. Semin Oncol. 1998. PMID: 9609104 Review.
-
Oxaliplatin-induced neurotoxicity: changes in axonal excitability precede development of neuropathy.Brain. 2009 Oct;132(Pt 10):2712-23. doi: 10.1093/brain/awp219. Epub 2009 Sep 10. Brain. 2009. PMID: 19745023
-
Incidence of atypical acute nerve hyperexcitability symptoms in oxaliplatin-treated patients with colorectal cancer.Cancer Chemother Pharmacol. 2012 Dec;70(6):899-902. doi: 10.1007/s00280-012-2006-8. Epub 2012 Oct 30. Cancer Chemother Pharmacol. 2012. PMID: 23108696
-
Lhermitte sign and urinary retention: atypical presentation of oxaliplatin neurotoxicity in four patients.Cancer. 2002 May 1;94(9):2434-40. doi: 10.1002/cncr.10500. Cancer. 2002. PMID: 12015768
-
Clinical management of oxaliplatin-associated neurotoxicity.Clin Colorectal Cancer. 2005 Apr;5 Suppl 1:S38-46. doi: 10.3816/ccc.2005.s.006. Clin Colorectal Cancer. 2005. PMID: 15871765 Review.
Cited by
-
Acute cold hypersensitivity characteristically induced by oxaliplatin is caused by the enhanced responsiveness of TRPA1 in mice.Mol Pain. 2012 Jul 28;8:55. doi: 10.1186/1744-8069-8-55. Mol Pain. 2012. PMID: 22839205 Free PMC article.
-
Oxaliplatin-induced coronary artery spasm: first report of an important side-effect.BMJ Case Rep. 2009;2009:bcr06.2008.0334. doi: 10.1136/bcr.06.2008.0334. Epub 2009 Feb 26. BMJ Case Rep. 2009. PMID: 21686854 Free PMC article.
-
Oxaliplatin-related neuropathy in Indian patients - no difference between generic and original molecules.Indian J Med Paediatr Oncol. 2016 Oct-Dec;37(4):271-277. doi: 10.4103/0971-5851.195745. Indian J Med Paediatr Oncol. 2016. PMID: 28144095 Free PMC article.
-
Wnt3a/YTHDF1 Regulated Oxaliplatin-Induced Neuropathic Pain Via TNF-α/IL-18 Expression in the Spinal Cord.Cell Mol Neurobiol. 2023 May;43(4):1583-1594. doi: 10.1007/s10571-022-01267-8. Epub 2022 Aug 8. Cell Mol Neurobiol. 2023. PMID: 35939138 Free PMC article.
-
DNA interstrand crosslink repair and cancer.Nat Rev Cancer. 2011 Jun 24;11(7):467-80. doi: 10.1038/nrc3088. Nat Rev Cancer. 2011. PMID: 21701511 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
